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USE OF IV ACETAMINOPHEN AS ADJUNCTIVE TREATMENT FOR POST- 
OPERATIVE PAIN AFTER EGG RETRIEVAL IN PATIENTS UNDERGOING  
FERTILITY TREATMENT 
MORGAN RAVEN GRAY 
ABSTRACT 
 
 This randomized, double-blind, placebo-controlled study was conducted to 
compare the effectiveness of intravenous acetaminophen vs. oral acetaminophen 
or placebo as an adjunct to opioids on lowering post-operative pain scores, 
discharge time, need for opioids, and opioid-related side effects, as well as 
assessing for any effects pain treatment has on embryological and pregnancy 
outcomes. Secondary analysis included identifying risk factors in patients that 
cause them to have worsening pain or minor relief from traditional pain 
management. This study was conducted at a single academic fertility center at 
Massachusetts General Hospital in Boston with a patient population of 159 
English-speaking women between 18-43 years old, undergoing oocyte retrieval 
as a part of In Vitro Fertilization procedure. Participants were randomly placed in 
one of three treatment groups to receive either 1000mg IV acetaminophen and 
PO placebo (Group A), IV placebo, and 1000mg PO acetaminophen (Group B), 
or IV and PO placebo (Group C) as pain control before oocyte retrieval 




operative visual analogue scale pain scores in the recovery room at 10 minutes, 
30 minutes, and discharge time. Using these values to measure the effectiveness 
of each treatment at improving post-operative pain. To assess the relationship, if 
any, between demographical or clinical factors and pain, we analyzed what 
factors were common in those experiencing high or low pain. We used the Visual 
Analog Scale (VAS) which has patients rank pain from 1-10. For this analysis, 
low pain is defined as those whose 10-minute post-operative pain score was less 
than 5 (VAS score <5/10) and high pain as those whose 10-minute post-
operative pain score is 5 or greater (VAS score 5+/10). Results showed that 
mean post-operative pain scores were similar between the study groups at 10 
minutes (A:2.3, B: 2.6, C:2.8, p=0.51). Timing of discharge was also similar (A: 
60.1 mins, B: 58.8 mins, C:57.6mins; p=0.76).  
Although not statistically significant, the mean post-operative opioid dose 
for patients in group A was less than half of that in Group B and C (0.24mg vs. 
0.59mg vs. 0.58mg; p=0.34) and fewer required rescue pain medication in the 
recovery room (4% vs. 19% vs. 15% respectively; p=0.24). There was a trend 
towards decreased side effects of constipation in Group A compared to Groups B 
and C (15% vs. 31% vs. 33%, respectively; p=0.07). There were no differences in 
embryological or early pregnancy outcomes between study groups. 
 An analysis of predictors of pain, patients with BMI >/=30kg/m2 (obese) 




surgeries, including pelvic laparoscopy and laparotomy, were associated with low 
post-operative pain (p=0.069 and p=0.025, respectively). Those who reported 
having pre-operative pain greater than zero were more likely to report lower post-
operative pain (p=0.002). There was no significant relationship between 
race/ethnicity, infertility diagnosis, and procedure length and pain. This study's 
findings showed no significant difference between post-operative pain scores or 
discharge times in women undergoing oocyte retrieval when given IV 
acetaminophen, PO acetaminophen, or a placebo. There were severe findings 
that suggested that IV acetaminophen may reduce the need for post-operative 
narcotics and lead to fewer opioid-related side effects, however these findings 
while large were statistically insignificant. The predictors of higher post-operative 
pain we found, including high BMI, no prior history of abdominal procedures, and 
lack of pre-operative pain, indicate that further investigation into these predictors 
could be beneficial. This information may allow physicians and anesthesiologists 
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The process of IVF  
 In Vitro Fertilization (IVF) is used to help individuals who are unable or 
have difficulty conceiving naturally for several reasons, including infertility, history 
of genetic illness, or health conditions.1-2 It involves several steps, including 
ovarian stimulation, which involves administering follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH), stimulating more than one oocyte to 
develop. When follicles are ready for egg retrieval, usually within 8-14 days, 
women will take human chorionic gonadotropin (HCG) to mature eggs.1 Patients 
are evaluated to ensure they have produced an adequate number of 
appropriately sized follicles developing. If conditions are met, the next step in IVF 
is to retrieve oocytes from the female. A needle connected to a suction device 
guided by transvaginal ultrasound is inserted through the vaginal wall and into 
the stimulated ovary. At this time, the needle will aspirate the egg and follicular 
fluid into the needle and then to a collection tube.2 If eggs are observed to be 
healthy and mature, they will be inseminated or injected with sperm to create an 
embryo. While the procedure is typically performed in less than 30 minutes and 
the patient is sedated, it is normal to experience some level of post-operative 
pain given its invasive nature.3 
 Since the procedure's reaction can vary from mild abdominal discomfort 




management plans, and pain medications are given during and after are usually 
dispensed based on patients or anesthesiologist preferences.4 The standard of 
care at Massachusetts General Hospital (MGH) for post-operative pain 
management in oocyte retrieval is vague. It involves routine anesthesia with 
analgesia as needed based on the patient's reported pain level by a visual 
analog scale (VAS) pain score (Figure 1). Specific analgesia can vary from 
opioids, benzodiazepines, non-steroidal anti-inflammatory drugs (NSAIDs), and 
oral and IV acetaminophen, depending on the anesthesiologist. There are no 
indications for which is appropriate or would be most effective related to 
variations in the patient's pain level. Research into specificity in pain 
management in oocyte retrieval is in its infancy. 
 
 
Figure 1: VAS Pain Scale. Image is provided to patients who are instructed to use to indicate 







Variation in post-operative pain 
 Variation in post-operative responses to pain is seen across surgeries in 
all fields, from minor to major procedures. While there are some expectations for 
each given procedure's mechanism, length and areas involved; the experience of 
pain is a separate, multifactorial force related to the physiology of pain 
transmission and an individual’s characteristics.5 Regarding oocyte retrieval, 
response to the procedure is often unpredictable. A study conducted by 
Frederickson et al. into subjective pain levels after egg retrieval showed 7% of 
the patients ranked pain as very or extremely painful, while other studies 
analyzed by Frederickson indicating over half characterized pain as unbearable. 
While 7% is a small group, it does indicate there may be factors that are 
contributing to higher pain levels in these patients specifically and, as such, may 
require additional interventions to alleviate pain during procedure.4 These factors 
can be related to the procedure or may have origins completed unrelated to IVF. 
Contributors to pain can range from pre-existing conditions or comorbidities and 
infertility's effect on women's psychological health to more recent experiences 
directly involved with the surgery. By better understanding contributors to pain, 
intervention can be personalized to consider these factors. Currently, the 
literature on how nonsurgical factors can affect IVF patient's pain levels is 
lacking. However, further investigation could be beneficial for more appropriate 




management, such as those seen in Frederickson's study, and improve surgical 
outcomes.  
 Frederickson’s study investigated certain traits that appear to be 
correlated to increased pain levels. The primary pre-operative contributors he 
found included patients who reported higher pain levels also report having 
negative gynecological experiences in the past and side effects to hormonal 
treatments in weeks leading up to the procedure.4 Additionally, gender 
comparison studies have shown that simply being female is a risk factor for 
higher pain perception.6,7 During surgery, factors including anxiety during 
retrieval, feeling lower levels of control, and long duration of procedure were also 
found to impact pain scores negatively.4 It is not uncommon for patients to repeat 
IVF after previous failures; these failures have been shown to cause increased 
stress, feeling lower levels of control, and increased depression. This suggests 
that women who must undergo oocyte retrieval multiple times could also be a risk 
factor for high pain.8 Many of the contributors he found had more to do with the 
patient's current mindset or stress, meaning pain can be significantly influenced 
between patients who receive the same procedure and medications.  
 
Issues with unregulated pain control 
 Given that oocyte retrieval is a minor outpatient surgery, post-operative 




often do not have standardized dosing for pain medications. As a result, pain 
interventions are usually based on either physician’s assumptions or a patient's 
subjective report after the procedure is complete.5 With the multitude of risk 
factors the population of IVF patients encompasses causing the wide variation in 
pain levels patients, the procedure does not have a clear superior type of pain 
control that fits all patient’s needs. However, as the procedure is deemed minor 
compared to others, there has not been much focus on personalizing pain 
treatments or how patients differ. With little information to predict how a patient 
may react to the procedure and basing medications at random, there is an 
increased chance for potentially under- or over-prescribing pain medication. Both 
of which have the potential to harm a patient significantly post-surgically. 
 
Undertreatment of pain 
 Although post-operative pain relief is primarily associated with maintaining 
a patient’s comfort, it also has an enormous impact on post-surgical recovery. 
Studies have shown that well-controlled pain allows for restoration of function to 
the area involved in the surgery and enhances recovery of being able to breathe 
and ambulate independently without limitations.9 Post-surgical pain has been 
connected to adverse events (AE) in surgeries such as impaired wound repair, 




Additionally, unmanaged pain has been shown to put patients at increased risk of 
developing chronic pain. 
 Chronic pain development can be mainly attributed to central nervous 
system (CNS) changes in an individual following surgical trauma and nerve 
injury. The use of pharmacological agents interrupts the central sensitization of 
pain, which reduces these changes. Development in chronic pain comes with the 
obvious recurrent, unmanageable pain but has also been shown to cause long-
term psychological distress, including anxiety, insomnia, and feeling of 
helplessness.9 A study by Reddi et al. investigating factors that are more likely to 
contribute to post-operative pain development regardless of procedure included 
repeated surgery, psychological vulnerability, pre-operative anxiety, and female 
gender.6 The majority of IVF patients are likely to have some, if not all, of these 
risk factors. Aside from the apparent female gender factor, it is not abnormal for 
IVF patients to require repeating the process and thus egg retrieval surgery more 
than once to implant a healthy embryo.1,4 It has also been seen that regardless of 
if infertility is a factor from the female or male partner, the female is significantly 
more likely to develop anxiety or sleep disorders.9 
 
Over-treatment of pain 
 Opioids are commonly used for peri and post-operative treatment, given a 




While opioids can be initially helpful to manage pain, there are several 
associated side effects, including drowsiness, post-operative nausea and 
vomiting, respiratory depression, and bladder dysfunction.11 While primarily 
unpleasant, these, like those we discussed earlier related to undertreated pain, 
could harm a patient's ability to recover after surgery.  
As the incidents of opioid use disorder (OUD) continue to rise, many in 
medicine have stressed the importance of research into substituting or 
decreasing the use of opioids across all surgeries.12 Many addiction disorders 
involving opioids initially start due to therapeutic exposures from prescriptions, 
with 80% of heroin use disorders reportedly beginning with the misuse of 
prescription opoids.12-13 While these drugs are regulated since they have become 
such a standard pain management tool, it is easy for providers to jump to using 
them to quickly treat pain without fully considering the potential risks associated 
with it. A recent look into geographic trends of opioid prescriptions and OUD 
showed women in the southern United States are at the highest risk of receiving 
opioid prescriptions while also being the highest area of opioid overuse and 
overdose deaths.13 A study conducted by Bortollo et al. measured the frequency 
of opioids dispensed within three days of retrieval and compared this with patient 
characteristics. After oocyte retrieval, most patients are discharged home without 
further pain prescriptions as pain is deemed manageable; however, those who 
still report high pain will be offered a prescription for further treatment at home. It 




after oocyte retrieval filled the prescription. Those with mood disorders, tobacco 
use, or antidepressant use were significantly more likely to fill a prescription than 
those without these diagnoses.5 As discussed above, women in IVF are more 
prone to psychological distress and, by this study's results, more likely to fill an 
opioid prescription.6-7,11 It is estimated that only about 1% of patients experience 
pain after the first day severe enough to warrant opioid use.13 So results such as 
those seen in Bortoletto with 11% requiring raise concern that these patients are 
dealing with pain may be influenced by more than just the procedure. Since 
psychological distress is also a risk factor for the development of OUD, these 
patients having prolonged unsupervised use of opioids at home raises the risk for 
misuse.5,13 
 The risk of OUD development by misuse of prescription opioids is not only 
to the patient but also those around them. Bicket et al. reviewed six eligible 
studies where participants underwent seven different surgical procedures and 
discharged with an opioid prescription. Results showed that 67-92% of 
individuals had unused opioids, which made up 42-71% of opioid tablets 
obtained. The majority of patients reported stopping due to adequate pain 
control, and 2/3 of patients with leftover opioids admitted to not disposing or 
storing them safely, with 20% admitting to sharing them with family.14 Beside 
those who admit to sharing their medications, it is also a high probability that any 
not properly secured pills could be taken and used by others in the home. The 




understanding of optimally predicting and treating post-operative pain. As 
research into alternatives has been on the rise within the last ten years in the 
setting of an increase in OUD, one method that is commonly successful in 
minimizing uncontrolled pain regulation, side effects, and substance use 
disorders has come from the multimodal treatment approach15. 
 
Diversity of adjunct non-opioids for multimodal analgesia 
 The use of multimodal analgesia has been more effective as it is patient-
centric and stresses the importance of considering the various contributes to 
pain.15 Currently, much research about pain medication focuses on one model. 
However, the addition of multiple medications has been proven to have additive 
or synchronous benefits, often together leading to more efficient pain 
management.9 Opioids are often standard practice in pain management control 
as they are exceptionally effective at treating pain. However, due to the risks and 
side effects, the addition of a non-opioid medication could minimize these effects. 
Since the introduction of multimodal analgesia, there has been an apparent 
decrease in opioid-related adverse events (ORAE).9 These non-opioids can vary 
from acetaminophen, NSAIDs, benzodiazepine, which each can contribute to 
pain control while minimizing the number of opioids patients require during and 
after surgery.16 While still new, research into multimodal pain management has 




significant differences between use with opioids versus only opioids.17-18 Those 
that focused on pain control, specifically in Obstetrics and Gynecology patients, 
have noted that further research into the relationship between pain medication 
and pregnancy outcomes should be the next step in further multimodal 
research.17 A multimodal approach is favored to ensure that pain is treated 
appropriately but does not have adverse effects on reproductive outcomes. 
 
Intravenous acetaminophen for pain management 
 When evaluating non-opiate medications to use in adjunct with opioids, a 
good candidate would allow for the reduction of opioid consumption without 
adverse effects on pain management, surgical outcomes, cost, and recovery. 
Intravenous acetaminophen (IV APAP) has been shown to satisfy these 
requirements in several outpatient surgical procedures. Given its rapid onset, low 
risk of side effects, and antipyretic as well as analgesic effects, it has the 
potential to be sufficient for treating pain from oocyte retrieval perioperatively and 
post-operatively.19 As the research of its use in the United States is in its infancy, 
with little if any related to oocyte retrieval in IVF patients, more information is 








 Compared to other pain management medications in the United States, IV 
APAP is new and has fewer studies conducted in the U.S. compared to other 
pain medications. As a result of limited research physicians and 
anesthesiologists are hesitant to implement it regularly as they are not as familiar 
with it. However, IV APAP has been approved in about 80 countries in Europe, 
Asia-Pacific, Middle East, Africa, and more. It has been approved for the 
management of mild to moderate pain or when used in adjunct with opioids to 
manage moderate to severe pain and reduce fevers in adults and children over 
the age of two.19 Significant adverse events associated with IV APAP use are 
rare and occur at an estimated rate of less than 1/10,000, while the rate of ORAE 
has been difficult to measure given variation but has been seen to be closer to 
1/10.15 
 
Decrease in opioid requirement and side effects 
 When previously implemented in OBGYN (obstetrics and gynecology) 
surgeries, there has been evidence that the addition of IV APAP does result in a 
decrease in opioid consumption. Urman et al. compared patients receiving IV 
APAP and opioids vs. opioids alone and saw a 12% decrease in opioid use in 
cesarean deliveries and hysterectomies with fewer incidences of side effects 




Hansen et al. performed a retrospective analysis of inpatient OBGYN studies 
between January 2009 and June 2015, comparing IV APAP and opioids vs. 
opioids alone, which observed an average of 8.2mg lower daily opioid use in 
patients.21 Another study by Stoudemire saw outpatient opioid consumption rates 
significantly reduced from 18% to 8.5% (p<0.001). More than 90% of IV APAP 
patients reporting their pain were well controlled and willing to receive the same 
regimen in any future surgeries.23 
 
Improved Pain Control 
 The addition of IV APAP to reduce adverse side effects and increase 
patients' safety does not have to come at the cost of pain management. In Khalili 
et al., the use of IV APAP peri- and post-operatively in patients undergoing lower 
extremity surgeries produced a significant decrease in pain scores six hours after 
surgery compared to opioids only (p<0.001).24 Several studies from varying 
surgical fields have shown similar findings indicating that IV APAP can bolster 








Length of Stay & Cost  
 As a result of improved pain, there has also been a positive effect in 
recovery time and the requirement of hospital resources related to implementing 
IV APAP. In hysterectomy patients, multimodal pain management with IV APAP 
resulted in a 0.8 day shorter LOS in patients (p<0.0001), with an average of 
$484.4 lower hospitalization costs (p<0.006).22 suggests that adjuncts of IV 
APAP could better help patients while also reduce the burden on hospital staff 
and administration by requiring less resource allocation to these patients.  
 
Comparison of IV APAP to PO and NSAIDs 
 IV APAP is only one of the adjuncts that have been used since research 
into multimodal pain management has risen in popularity. There are indications 
compared to more well-known, popular options such as PO APAP (oral route 
acetaminophen) and NSAIDs, IV APAP may be more effective and safer to use 
for post-operative pain.  
 
Oral administration of acetaminophen 
While PO APAP may appear to be an easier administrated route than IV, 
the IV formulation is more appropriate for oocyte retrieval. It has been more 




mobility which are commonly associated side effects of the procedure and opioid 
use.20 When compared with PO APAP in cesarean and hysterectomy patients, IV 
APAP was associated with a shorter length of stay, reduced risk of ORAE's and 
opioid consumption.22 The same study also indicated no significant difference in 
pharmaceutical costs, which is meaningful given one of the frequently mentioned 
cons of IV acetaminophen is that it is commonly believed to be more expensive 
than the oral route. Although net cost IV APAP is more expensive than PO and 
less likely to be reimbursed by insurance companies, this difference may be 
negligible due to the difference in bioavailability. The bioavailability of IV APAP in 
the cerebral spinal fluid (CSF) compared with PO APAP after administering 1 
gram over 6 hours is 24.9 vs. 14.2 uq*hr/mL. IV was also observed to enter the 
CSF earlier with greater penetration allowing for more fast-acting and more 
significant effect than PO.26 When a situation calls for rapid onset of pain 
management, such as in a post-operative setting, the composition of IV allows for 
faster administration, time to meaningful pain relief, and time to maximal pain 
relief.9 
 While the risk of overdose always exists, IV APAP has been observed to 
be safer than the same dose of PO. IV creates a lower accumulation of 
acetaminophen’s toxic metabolite (n-acetyl-p-benzoquinoneimine), with a peak 
concentration in the liver being 50% less than PO.27 Currently, the chance of 






 While grouped into the same category as APAP when discussing pain 
management, the properties and function of NSAIDS are different. NSAIDs 
function primarily as an anti-inflammatory medication while APAP is an 
antipyretic, meaning while they both have similar outcomes of pain relief, they do 
so by different methods. The use of NSAIDs, while common, is associated with 
an increase in specific adverse events, including GI bleeding, GI mucosal 
damage, renal impairment, and post-operative bleeding.9 They are 
contraindicated in many practices for those undergoing a fresh embryo transfer, 
given their possible influence implantation. NSAIDs are also not suggested for 
patients with comorbidities involving bleeding disorders and kidney dysfunction.20 
IV APAP does not have similar side effects and can be taken by all patients 
undergoing IVF, making it a better subject for pain management study. 
 
Limited research 
 Currently, research into the use of non-opiate alternatives for peri- and 
post-operative pain management is highly desirable due to the current rise of 
OUD and its common connection to individuals who have previously received 
prescription opioids.28 IV APAP can be widely successful in addition to post-
operative analgesia in numerous hospital settings. As discussed above, it has a 




operative care. However, there is relatively low clinical data comparing its 
efficiency to other agents and ability to be a sufficient substitute or addition, 
especially in the field of OBGYN and reproductive endocrinology. For that 
reason, it is crucial to contribute to literature regarding its efficiency compared to 
more commonly accepted oral administration and opioids19. Less pain 
improvement research is conducted for minor outpatient procedures such as 
oocyte retrieval as they are assumed to be well tolerated. by patients. However, 
as the population often exhibits higher stress and is undergoing a sensitive 
procedure, oocyte retrieval is a great candidate to investigate more specified pain 















This study's primary goal is to assess the efficiency of pre-operative IV vs. 
PO APAP compared to the current standard of care, placebo, for pain control 
after oocyte retrieval. We hypothesized that patients who receive IV APAP would 
have lower pain scores, require fewer rescue medications, exhibit lower narcotic 
use, have shortened time to discharge from the post-anesthesia care unit 
(PACU), and decreased the occurrence of opiate-related side effects. As a 
secondary analysis, we hope to use patients' information to identify potential 

















This study is a block-randomized, double-blind, placebo-controlled study 
conducted over approximately nine months at the MGH Fertility Center. Inclusion 
criteria included English-speaking patients, 18-43 years old and undergoing 
ovarian stimulation and oocyte retrieval. Patients were excluded if they had 
documented allergy to acetaminophen or opiates, any history of liver disease or 
renal impairment; a history of chronic opiate use or alcohol dependence; chronic 
pain disorder; or weight less than 50 kilograms (kg). Also, per the clinic's 
protocol, no patients undergoing oocyte retrieval had a body mass index (BMI) 
greater than or equal to 40kg/m2. Patients who underwent more than one egg 
retrieval during the time course of the study were not allowed to participate in the 
study more than once. We reviewed electronic health records to evaluate for 
inclusion/exclusion criteria.  
 
Patient recruitment 
IVF Patients from the reproductive endocrinology practice at MGH with 




were informed of the study at the time of their baseline ultrasound and provided 
informational sheets outlining study goals. Patients were assured they could 
withdraw from the study at any time, and it will not impact their infertility treatment 
or cycle management. We also reassured patients that they would receive the 
standard care of anesthesia, with all perioperative pain treated. They were 
offered the opportunity to enroll in the study by a licensed MD at their subsequent 
IVF cycle monitoring visits.  
 
Ovarian stimulation and retrieval protocols 
The study patients underwent a standard infertility work-up as previously 
described.29-32 Protocols for controlled ovarian hyperstimulation included luteal-
phase gonadotropin-releasing hormone (GnRH) agonist, GnRH-antagonist 
downregulation, or GnRH agonist flare protocols, with follicular synchronization 
and pituitary down-regulation with oral contraceptive pills as clinically indicated, 
were followed. During treatment with recombinant gonadotropins, patients were 
monitored with transvaginal ultrasound to assess follicular measurements and 
endometrial thickness, and serum estradiol (E2).31 Once at least three follicles 
reached 16mm or more in diameter and the E2 level was > 600 pg/mL, 
intramuscular human chorionic gonadotropin (hCG) or subcutaneous leuprolide 
acetate was administered to induce oocyte maturation. The patients underwent a 
transvaginal ultrasound-guided oocyte retrieval 36 hours later.30 All agreed to 




Compliance was confirmed before the administration of study medication and 
data collection on the day of the procedure. 
Couples underwent IVF with conventional insemination or IVF with 
intracytoplasmic sperm injection (ICSI) as clinically indicated between 3-5 hours 
post oocyte thaw or retrieval. Fertilization was assessed between 16 and 18 h 
after insemination. According to clinic protocol, fresh embryo transfer was 
performed on day three or day five based on the number of embryos available 
and their quality. Intramuscular progesterone, 50mg per day, was begun the day 
after oocyte retrieval for those undergoing a fresh transfer and continued until ten 
weeks gestation if conception occurred. A positive pregnancy test was defined as 
a serum β-hCG level >6 mIU/mL, typically measured 17 days (range 15–20 days) 
after oocyte retrieval. Clinical information was abstracted from the patient's 
electronic medical record by the research staff. 
 
Randomization and data collection 
When the enrolled patient's egg retrieval was scheduled, study staff 
ordered the research medications in EPIC and notified both the IVF team and 
research pharmacy via secure email. The research pharmacy generated a 
computer-generated blocked randomization scheme. A randomized number was 
entered into each study patient's EPIC medication order corresponding to one of 




for each patient based on the designated study group, and the IVF care team 
was blinded to medications and groups.  
When patients presented for oocyte retrieval, a VAS (1-10) pain score was 
recorded for each study patient. Each participant received a PO medication and 
IV medication preoperatively, depending on their study group. Randomized 
patients were administered 1000mg IV acetaminophen and PO placebo (Group 
A), 1000mg PO acetaminophen and IV placebo (Group B), or PO and IV placebo 
(Group C) by nurse approximately 30-60 minutes before the procedure. A 
research pharmacy packaged the IV and PO medications with identical 
appearance keeping the patients, study staff, IVF physicians, and 
anesthesiologists blinded to assigned treatment. The time that medications were 
given was recorded. 
All study patients received monitored MAC anesthesia with propofol during 
the oocyte retrieval with opioids such as fentanyl for pain control. Time of arrival 
to the post-operative room, VAS pain score at 10 minutes post-operatively, 30 
minutes post-operatively, and discharge, and time of discharge were recorded on 
the data collection sheet. If a patient reported a post-operative VAS pain score 
greater than 6, they were provided rescue medication as needed.  Rescued 
medications are defined as additional opioids, including fentanyl or PO 
oxycodone. The dose and time of rescue medication administration and if a 
patient required a prescription for pain medication were recorded. As some 




allowed to take NSAIDs, no study patients were given IV ketorolac post-
operatively. After same-day discharge, patients were called on post-operative 
day two (POD2) by study staff to assess their recovery. VAS pain score on POD1 
and POD2, symptoms such as nausea or constipation, and any opioid 
medication use were recorded.  
 
Variables 
In addition to the variables mentioned above collected by nurses and 
study staff, the electronic medical records (EPIC) were reviewed to record 
medical history, including any psychological disorders and IVF cycle history, 
along with embryology findings and pregnancy outcomes. Analysis of 
demographics allowed for confirmation that our groups were truly random and 
opportunity for secondary analysis of potential contributing factors to pain. 
Additionally, by analyzing how the remainder of a patient’s IVF cycle went, we 
could ensure treatment did not harm pregnancy outcomes. The primary study 
endpoints were post-operative pain levels in the recovery room, with an 
additional corrected pain score which reflects the difference between the post-op 
and pre-op score to reflect the raw change in pain scores. Secondary endpoints 
included: perioperative and post-operative opioid requirement (in IV morphine 
milligram equivalents, MME); post-operative rescue pain medication requirement 
(MME); time to rescue medication use; POD1 and POD2 pain scores; post-




MII) oocytes, fertilization rate (number 2 pronuclear (2PN) embryos/number MII), 
number usable (transferrable or frozen) embryos, and blastocyst rate (number 
blastocyst/number 2PN)]; and a positive pregnancy test. 
 
Analysis 
 Evaluation of our primary hypothesis was done by assessing the 
difference in pain scores using Fisher's Exact and chi-square tests as 
appropriate. A multivariable regression model was performed to control potential 
confounding variables such as medical comorbidities, discharge time, oocytes 
retrieved, and maternal age. Using a power analysis using VAS scores and 
discharge time from 13 patient’s data, we estimated that we would need a 
sample size of 159 patients to detect a 10% difference in mean recovery time 
and an absolute difference in VAS pain scores of 1.7 or greater between 
treatment groups and Group C with 80% power, based on two-sample t-tests at 
the 0.025 two-tailed significance level, where this significance reflects an 
adjustment for the two treatment group comparisons with the control group. 
Alternatively, assuming that the mean pain scores for the three groups are 1, 1.5, 
and 2.5, respectively, we would have 80% power to detect that the three group-
means are different based on a one-way analysis of variances (ANOVA) at the 




aimed to enroll 58 patients in each of the three study groups (n=174) to evaluate 
primary outcome data for a minimum of 159 patients.  
 This analysis was performed per protocol. The continuous outcome 
measures were compared between study groups using a one-way ANOVA, while 
chi-squared tests were used for categorical variables. All analyses were 




Independent monitoring of source data 
 Data was collected by study staff from the Department of Reproductive 
Endocrinology and Infertility. Consenting patient information was logged into a 
secure data form on a Partner's password-protected computer accessible only to 
study staff. Data collection sheets completed during the procedure were stored 
securely in a lockbox on Yawkey 10 at MGH during study recruitment and then 
entered RedCap, a secure online database program. Identifying information was 
removed and replaced with a unique patient ID number. Only the PI and research 
team had access to the online and hard copy database. A binder containing the 
data collection sheets was removed monthly by a study staff member and PI to 
remove identifying information from sheets. The PI was responsible for 




required to pause during the recruitment period due to COVID-19 but could 
resume soon after with no other indications that alterations were required. 
 
Safety monitoring 
PI was responsible for monitoring the study and recording possible 
Adverse Events (AE) that could be attributed to the study protocol. The president 
was set that if three subjects experienced a grade 2 or greater AE possibly 
related to study procedures, the study would be paused to evaluate the safety of 
continuing enrollment fully. If such an event were to occur, the PI would be 
responsible for reviewing the data and determining whether the research should 
be altered, paused, or stopped. If any unanticipated problems involving risks to 
subjects or others or decisions to stop enrollment arose, PI planned to report 





The research assistant and IVF Fellows oversaw the collection and 
monitoring of data collection forms and the RedCap database monthly for 
accuracy and completeness. The PI conducted a periodic review of the case 
report forms and source documentation. The study staff met after 50% desired 








Patients were recruited between 12/17/2019 and 10/4/2020, with a pause 
between 3/12/2020 and 6/25/2020 due to institutional research restrictions during 
the coronavirus 2019 (COVID-19) surge. Of the 301 patients screened for 
eligibility at their baseline IVF ultrasound, 272 were eligible for participation. Of 
eligible patients, 181 consented to participate in the study (66.9%). After 
completing the ovarian stimulation protocol, 161 consenting patients were 
randomized and underwent oocyte retrieval. One hundred fifty-nine consenting 
patients completing the study, Groups A, B, and C had 53, 54, and 52 patients, 
respectively. Two patients were disqualified after requesting Toradol post-






Figure 2: Patient Recruitment Outcomes. Figure above summarizes the evaluation of patients 
as viable sources for data collection throughout the process of study, from initial screenings to the 
procedure. 
 
Demographical and clinical characteristics of the study population 
Our sample population analyzed in this study consisted of 159 women 
with a mean age of 35.65 years. The majority of our participants (77%) identified 




Regarding ethnicity, 5% of patients identified as Hispanic, 4% identified as Other, 
and 91% did not specify. Our study group had a mean body mass index of 25.28 
kg/m2. IVF is used for various reasons related to trouble conceiving that can be 
attributed to either the male or female partner. In our study group, 39% of 
infertility was attributed to the male factor, 46% to the female factor, 9% 
idiopathic, and 31% attributed to other unlisted causes. The groups did not differ 
in baseline demographic or clinical characteristics (Table 1). Perioperative oocyte 
retrieval and embryo transfer characteristics were also similar between study 
groups (Table 2). 









Age, years (mean) 35.2 (4.1) 35.7 (4.5) 36.0 (4.0) 
Race (N, %) 
   
White 41 (77%) 43 (80%) 39 (75%) 
Black 2 (4%) 2 (4%) 1 (2%) 
Asian 5 (9%) 4 (7%) 6 (12%) 
Ethnicity (N, %) 
   
Hispanic 3 (6%) 1 (2%) 4 (8%) 
Other 2 (4%) 3 (6%) 2 (4%) 
Not specified 48 (91%) 50 (93%) 46 (88%) 
Body mass index (mean, kg/m2) 25.4 (4.7) 24.9 (4.1) 25.6 (4.9) 
Nulliparous (N, %) 41 (77%) 39 (72%) 43 (83%) 
Day 3 FSH (mean, IU/L) 7.4 (2.8) 7.1 (2.9) 7.5 (2.8) 
AMH (mean, ng/ml) 2.9 (2.9) 3.0 (2.4) 2.4 (1.7) 
Retrieval number (mean) 1.6 (1.0) 1.6 (1.1) 1.6 (1.1) 








Infertility Diagnosis (N, %) 
   
   Male factor 24 (45%) 18 (33%) 20 (38%) 
   Female factor 23 (43%) 25 (46%) 25 (48%) 
  Tubal factor 4 (8%) 4 (7%) 4 (8%) 




  Decreased ovarian reserve 11 (21%) 9 (17%) 12 (23%) 
  Uterine factor 5 (9%) 4 (7%) 3 (6%) 
  Endometriosis 2 (4%) 2 (4%) 2 (4%) 
   Idiopathic 5 (9%) 4 (7%) 7 (13%) 
   Other/Non-infertility 16 (30%) 22 (41%) 12 (23%) 
IVF Stimulation protocol (N, %) 
   
  Lupron down-regulation  8 (15%) 5 (9%) 11 (21%) 
  Flare 16 (30%) 11 (20%) 9 (17%) 
  GnRH antagonist 25 (47%) 34 (63%) 28 (54%) 
Patch 4 (8%) 4 (7%) 4 (8%) 
 
Table 2. Oocyte retrieval and embryo transfer characteristics  
Group A Group B Group C 
Pre-operative pain score 1.0 (1.5) 1.3 (1.7) 1.0 (1.3) 








Procedure length (min) 13.5 (5.9) 13.7 (5.3) 14.1 (6.6) 
Number of oocytes retrieved 12.6 (8.8) 13.4 (8.7) 11.4 (5.9) 
Embryo transfer type (N,%) 
   
D3 fresh transfer 7 (13%) 5 (9%) 8 (15%) 
D5 fresh transfer 12 (23%) 13 (24%) 20 (38%) 
Embryo cryopreservation 27 (51%) 26 (48%) 17 (33%) 
Oocyte Cryopreservation 7 (13%) 10 (19%) 7 (13%) 
Number of embryos transferred in fresh cycles 
(mean) 1.6 (0.9) 1.7 (0.8) 1.5 (0.8) 
Post-operative complication (N, %) 0 0 0 
 
Primary and secondary outcomes 
 There were no differences between study groups concerning post-
operative pain at 10 minutes, 30 minutes, and discharge, or time to discharge 
(Table 3). Despite the similarities, only 8% of patients in Group A required rescue 
medications compared to 19% and 15% in Groups B and C, respectively, but this 
difference was not statistically significant (p=0.24). Group A received the lowest 
amount of absolute total perioperative dose (8.0 mg vs. 8.9 mg vs. 8.6 mg), but 




were similar between the study groups, and no patients available for POD2 
follow-up required opioid medication at home. There was a trend towards the 
lower occurrence of post-operative constipation in Group A compared to Group B 
and C (p=0.072). 
Table 3. Primary and secondary perioperative outcomes of women undergoing 
oocyte retrieval  
Group A Group B Group C P-
value 
Post-operative pain score 
    
10 minutes 2.3 (2.4) 2.6 (2.5) 2.8(2.1) 0.51 
30 minutes 2.9 (2.3) 3.0 (2.2) 3.0 (1.8) 0.94 
Discharge 2.5 (1.8) 2.6 (1.8) 2.7 (1.3) 0.71 
Corrected post-operative pain score 
    
10 minutes 1.3 (2.4) 1.3 (2.8) 1.8 (1.8) 0.40 
30 minutes 1.9 (2.2) 1.7 (2.5) 2.0 (1.7) 0.76 
Discharge 1.5 (1.8) 1.2 (2.3) 1.8 (1.4) 0.36 






Total intraoperative opioid dose 
(MME)b 7.8 (3.7) 8.3 (3.4) 8.0 (4.1) 0.80 
Total postoperative opioid dose 
(MME)b 0.24 (1.0) 0.59 (1.6) 0.58 (1.5) 0.34 
Total perioperative opioid dose 
(MME)b 8.0 (4.0) 8.9 (3.7) 8.6 (3.6) 0.50 
Rescue medication required 4 (8%) 10 (19%) 8 (15%) 0.24 
Time to rescue medication (min) 15.8 
(16.7) 14.1 (9.5) 
17.6 
(13.3) 0.84 
Pain medication prescription needed 0 (0%) 1 (2%) 1 (2%) 0.61 
POD2 pain scorec 2.0 (2.5) 1.8 (1.8) 1.7 (1.4) 0.82 
Postoperative nausea 3 (6%) 4 (7%) 2 (4%) 0.73 
Postoperative constipation 8 (15%) 17 (31%) 17 (33%) 0.07 
Home opioid use 0 (0%) 0 (0%) 0 (0%) -- 
aPost-operative pain score minus pre-operative pain score 
bIV morphine milligram equivalents (MME) 








 Table 4 displays data obtained from the patient's electronic medical 
records regarding the study participant's IVF process outcomes. There was no 
significant difference in fertilization rate, number of usable embryos, blastocyst 
rate, positive pregnancy tests, and clinical pregnancy rate. 
 
Table 4. Embryology and early pregnancy outcomes of study participants  
Group A Group B Group C P-
value 












Number usable embryos (mean) 5.4 (4.9) 5.7 (6.6) 4.5 (3.6) 0.49 














Clinical pregnancy rate 
(#clinical pregnancy/#fresh transfer 




aOf women who underwent a fresh transfer (n = 63) 
Predictors of pain scores 
 Analysis of pain scores 10 minutes post-op of our entire sample 
population (n=159) for a relationship between certain demographic and clinical 
information was conducted. This was to assess if any factors were associated 
with low or high post-operative pain scores. Low pain was defined as VAS pain 
scores less than five, and high pain was defined as VAS pain scores equal to or 




was compared with the original and corrected post-operative pain score. Table 4 
is split between uncorrected pain scores and corrected pain scores. As 
mentioned above, corrected pain scores are the difference between the post-op 
and pre-op score to reflect the raw change in pain scores. This accounts for the 
differences that could be attributed to pre-operative pain unrelated to treatment. 
 
Demographic data 
 There was no significant difference in pain scores related to 
demographical data, including age, race, ethnicity, and partner type between 
study groups. However, patients with high BMI (obese) made up a significantly 
greater portion of those who reported high pain scores (31%) than those who 
reported low pain scores (11.6%) (p=0.009). The relationship between BMI and 
corrected post-op pain scores did not significantly differ (p=0.78). 
 
Medical history 
Before oocyte retrieval, patients who had a laparotomy were significantly 
more likely to have a corrected post-operative pain score at 10 minutes greater 
than or equal to 5 (p=0.025). Additionally, those who had prior pelvic laparoscopy 
tended to have higher corrected pain scores than those without; however, this 




were more likely to report high corrected pain scores; however, this trend was not 
statistically significant (p=.10). Those currently taking benzodiazepines were 
more likely to report high post-operative uncorrected pain scores (p=0.04). 
Infertility diagnoses and whether a patient was nulliparous or not did not have a 
significant effect on pain scores. 
 
Procedural  
Patients who had a pre-operative pain score greater than 0 were 
significantly more likely to have a low corrected post-op pain score after 10 
minutes (p=0.002). Those who reported low post-operative pain had, on average, 
a lower pre-operative pain score (average of 1.2) compared to those who 
reported high post-operative pain (average of 0.35) (p=0.027). Additionally, those 
who received more opioids during the procedure were significantly more likely to 
report low pain scores in both corrected and uncorrected pain scores (p=0.021 
and p=0.006). There was no difference in pain scores related to the number of 
oocytes retrieved during the procedure (p=.98). There was no difference in pain 











































Race (N, %)   0.69   0.44 
White 





Black 4 (2.9%) 1 (5.9%)  4 (3.1%) 1 (3.4%)  
Asian 
14 (10%) 1 (5.9%)  
14 14 
(10.9%) 1 (3.4%)  
Ethnicity (N, %)   0.1   0.27 
Hispanic 8 (5.7%) 0 (0%)  8 (6.2%) 0 (0%)  
Other 5 (3.6%) 2 (11.8%)  6 (4.7%) 1 (3.4%)  
Not specified 






index    (kg/m2, 
% >/=30 
(obsese)) 21 (15%) 3 (17.6%) 0.78 
15 
(11.6%) 9 (31%) 0.009 
Partner type 
(N,%)   .93   .89 
Male 





Female 1 (.7%) 0 (0.0%)  1 (.8%) 0 (0%)  
None  
23 (16.4%) 3 (17.6%)  
21 
(16.3%) 5 (17.2%)  
H/o anxiety or 
depression 
(N,%) 23 (16.4%) 4 (23.5%) 0.46 
21 
(16.3%) 6 (20.7%) 0.57 
Prior pelvic 
laparoscopy 
(N,%) 8 (5.7%) 3 (17.6%) 0.069 8 (6.2%) 3 (10.3%) 0.43 
Prior 
laparotomy 6 (4.3%) 3 (17.6%) 0.025 5 (3.9%) 4 (13.8%) 0.037 
Medication: 
SSRI/SNRI 





Benzos (N,%) 5 (3.6%) 1 (5.9%) 0.64 3 (2.3%) 3 (10.3%) 0.04 
Nulliparous 






Diagnosis (N,%)       
   Male factor 





   Female factor 





Tubal factor 10 (7.1%) 2 (11.8%) 0.5 8 (6.25) 4 (13.8%) 0.16 
Ovulatory 
dysfunction 19 (13.6%) 4 (23.5%) 0.27 
17 
(13.2%) 6 (20.7%) 0.3 
Decreased 
ovarian reserve 30 (21.4%) 2 (11.8%) 0.35 
28 
(21.7%) 4 (13.8% 0.34 
Uterine factor 10 (7.1%) 2 (11.8%) 0.5 10 (7.8%) 2 (6.9%) 0.88 
Endometriosis 5 (3.6%) 1 (5.9%) 0.64 4 (3.1%) 2 (6.9%) 0.33 
  Idiopathic 
15 (10.7%) 1 (5.9%) 0.53 
14 
(10.9%) 2 (6.9%) 0.52 
    Other/Non-

















mean) 13.6 (5.3) 14.7 (9.6) 0.43 13.7 (5.5) 14 (7.7) 0.8 
Total intraop 
opioid dose 














 The purpose of this study was to assess the efficacy of implementing IV 
acetaminophen as an adjunct to opioids as a routine peri- and post-operative 
pain management regimen for women undergoing oocyte retrieval. We 
hypothesized that those who receive IV APAP would have less pain, reduced 
narcotic use, shorter length of stay, and a decrease in opioid-related side effects 
compared to those who received opioids only and opioids and PO APAP. 
Additionally, as the overarching goal was to contribute further to research into 
multimodal pain management methods, which focus on considering the 
numerous factors that contribute to an individual’s post-operative pain, we hoped 
to be able to use data to assess if factors such as demographical information, 
medical history or patient experience related to increase or decreased pain in 
patients. Both goals help provide information to ensure patient’s pain after oocyte 
retrieval is not being over-or under-treated and patients are given the best means 
of recovering.  
 
Treatment influence on post-operative patient experience 
Although we did not see a significant difference between our control group 
(Group C) and IV APAP treatment group (Group A), this data could still be 




to opioids. While not statistically significant, those in Group A showed less opioid 
consumption compared to other groups, and patients had significantly fewer 
instances of post-operative constipation. Furthermore, fewer patients in Group A 
required rescue medications than other groups meaning they did not have to take 
more opioids than that given perioperatively. Lower requirement of rescue 
medications suggests that patients can get the same level of pain management 
while minimizing the requirement of opioids and thus minimizing the risk of side 
effects and OUD.  
 While we anticipated that time to discharge would decrease in the IV 
APAP group, all three groups had similar discharge times, which on average 
were close to an hour after the procedure. Previous studies with IV APAP in 
Hysterectomy patients did see a statistically significant decrease in length of 
stay. However, this may be attributable to expectations that hysterectomy 
patients need to be carefully monitored after the procedure and sometimes 
expected to stay up to 2 or 3 days.20,22 Since oocyte retrieval patients’ pain is 
usually at a level comfortable for discharge so soon after the procedure, there is 
likely not much more reduction in time possible with medication changes. A 
better evaluation in future research might be to look at if patients required a visit 
to an emergency department or primary care providers within a month of the 
procedure, indicating they needed further inpatient care. This study did not 
directly look at differences in cost between treatment groups. However, previous 




did not differ, IV APAP was associated with decreased hospitalization costs.22,33 
Evidence of lower length of stay and hospital costs can indicate that patients and 
hospitals could benefit from the addition of IV APAP even if not directly by pain 
management. 
 
Treatment influence on IVF outcomes 
 To find the more effective pain management regimens, we also wanted to 
ensure that any intervention we did would not negatively impact the procedure's 
overall goal, egg retrieval and eventually implantation and pregnancy. We were 
not concerned about this as there have been no studies to our knowledge that 
have related differences in IVF outcomes to IV APAP or other means of pain 
management. However, we followed up patient's medical charts to observe how 
the remainder of their IVF procedures went. Fortunately, there were no 
differences seen in patient's results at any point in the process after their egg 
retrieval in our three groups (Table 4). Although we were expecting this, it is 
essential to guarantee, as we saw from previous research discussed above, that 
poor IVF outcome and the need to restart the IVF process and undergo a second 






Potential predictors of pain 
 A unique secondary analysis that presented itself due to our study design 
was the ability to analyze this patient population to see if any factors positively or 
negatively contributed to the patient's pain. Information into possible predictors of 
pain will hopefully aid providers or those in future studies to recognize and 
predict the reaction a patient may likely undergo due to their “risk factors” or traits 
that may contribute to their pain sensitivity. These factors were examined without 
consideration of treatment groups. 
 
BMI 
 Our study showed that 31% of those who reported having a pain score of 
5 or greater (high pain) 10 minutes after the procedure were considered obese 
with a BMI greater or equal to 30kg/m2. Previous research has indicated that 
those with obesity are at higher risk of obstructive sleep apnea, which may 
influence their reactions to sedatives and supplemental oxygen.34 Additionally, 
obese women undergoing IVF treatments have been seen to have a lower 
success of implantation, pregnancy, and live birth rates which could cause them 
to have to undergo several rounds of IVF, potentially causing an increase in 
stress.35 With this information, these patients may benefit from alternative 




be easily explained is a positive relationship between those who received more 
opioids and those reporting lower post-operative pain. 
  
Prior abdominal surgeries 
 Patients who had undergone a previous laparotomy or pelvic laparoscopy 
were more likely to report low post-operative pain scores. This can be attributed 
to these patients having likely experienced pain after oocyte retrieval like those 
past surgeries as they occurred in similar areas. However, it is interesting that 
previous research had indicated that patients who underwent multiple oocyte 
retrievals experienced worsening pain, but this could be due to the stress or 
anxiety of having to undergo another IVF procedure.7 This evidence could mean 
those who have experienced abdominal surgeries in the past may be better able 
to handle the pain than those with no surgical experience.  
 
Mental Health/ Anti-Depressant Use 
 Patients currently taking benzodiazepines were significantly more likely to 
report high pain after the procedure. Those taking SSRI (selective serotonin 
reuptake inhibitors), while not statistically significant, tended to report high pain 
after the procedure. As these are related to the treatment of anxiety and 




mental health disorders being at higher risk of requiring pain medications and 
developing OUD even if never previously taking them.4,9 Providers could use this 
information to expect a higher incidence of pain and minimize opioid 




 Two unexpected results observed were those who reported feeling any 
pre-operative pain (VAS>0) were more likely to have a low post-operative pain 
score and those in the low pain group had a significantly higher pre-operative 
pain score than the high pain group with 1.2/10 vs. .35/10. This is unexpected as 
we assumed that those already in pain would feel worse after experiencing more 
pain. It is possible that patients who were already feeling unprompted pain were 
more prepared for the onset of pain than those who were feeling fine. While we 
did not ask our patients the source of their pre-operative pain, (e.g., due to 
chronic pains or comorbidities such as endometriosis), it is possible that these 
patients may have a higher pain tolerance. As a result, they were able to handle 
the pain associated with surgery better. These results could also be a negative 
side effect from our groups of high and low pain having very different sample 





Traits unrelated to increase or decrease in pain 
 Another interesting finding was that neither infertility diagnosis nor number 
of previous pregnancies had an effect on levels of post-operative pain. We 
speculated that those with endometriosis and likely more accustomed to pain in 
their abdominal region or those who had undergone pregnancy in past may 
tolerate pain better than others of different diagnoses. However, we found no 
difference in post-procedural pain scores. The reasoning behind this could be 
supported by a study by Baghianimoghadam regarding the mental health of 
infertile women, where women exhibited similar amounts of high stress, anxiety, 
and guilt related to infertility regardless of diagnosis.7 If diagnosis does not have 
a large impact on stress levels, which has been observed to correlate to 
worsening pain, it may not have a large impact on pain experiences.  
 
Study design and potential for future research 
This study was conducted as a double-blind, placebo-controlled 
randomized design which allowed for control of possible confounding variables 
during the study. We are confident that all results collected accurately depict 
findings related to the specific variables designated in the tables. Initially, the 
study and recruitment were paused due to the onset of the COVID-19 pandemic 
in the spring of 2020. Despite the initial setback, we were able to meet the 




patients. With 161 patients presenting for oocyte retrieval, only two patients 
needed to be excluded from final data due to their specific request for Toradol. 
The remaining 159 patients completed the procedure, and two-day follow up 
within the guidelines outlined in our procedure. 
 This study was limited by anesthesiologist concern for possibly 
undertreating pain. Typical practice often includes providing pain medication 
before/during surgery as a preventative measure and avoiding patients needing 
to request pain medication/having a high pain score. Because the 
anesthesiologists were blinded to the study groups, they typically gave their 
routine medication regimen, which often included fentanyl. This practice of opioid 
administration may have reduced our ability to see differences between our 
outcome groups. 
 While the results of this study showed insignificant differences between 
treatment plans, the study data may still be sufficient evidence that the use of IV 
APAP in oocyte retrieval or other fertility procedures can benefit patients and 
providers and calls for future investigations. As we have seen, patients 
undergoing IVF are a susceptible population with a higher risk of mental health 
issues, misuse of opioids, and experience of high post-operative pain. As such, 
finding ways to minimize opioid use while still providing the same level of pain 
management is significant for this population. As this group varies greatly in pain 
from mild to severe, research into causes of some patients to experience 




high success of treating these causes is highly desirable.  It is worth creating 
more specialized pain treatment that optimizes pain control and minimizes side 
effects without needing as much patient observation in the hospital. Less 
requirement for inpatient care will allow hospitals and patients to save on care 
costs as well as allow for an increased number of patients the hospital can care 
for by more quickly freeing up hospital staff. 
As the need for hospitalization and medical care continues to grow, and 
further thinking is constantly being put towards maximizing efficiency, research 
into pain predictors can serve to create more personalized pain management. 
Additionally, the need for investigations into the use of non-opioid alternatives 
has also grown to combat the increased occurrence of OUD after patient's use of 
prescribed opioids. Currently, oocyte retrieval patients specifically have seen 
great diversity in peri- and post-operative care trends, with some receiving too 
little pain management, thus impacting their ability to recover and others 
receiving too much, putting them and those around them at risk for OUD. As the 
population of those undergoing IVF has multiple physiological and psychological 
contributions to their pain and post-operative experience, the current "one size 
fits all" use of opioids is not the optimal or safest way to treat this population.  
While comparing IV APAP and PO APAP as adjuncts to opioids as well as 
opioids alone did not significantly affect pain scores, the ability of IV APAP to 
maintain the same level of analgesia while suggesting the ability to decrease 




use as an adjunct to opioids. Additionally, as this study only looked at short-term 
outcomes, it is possible that as IV APAP is less toxic on the liver compared to PO 
APAP, it may be overall better in improving a patient's long-term health. 
Currently, much of the literature focuses on differences in pain levels, costs, and 
length of stay as a judgment of efficiency. However, it has been shown that the 
biochemical properties of IV APAP compared to PO APAP and other pain 
management medications like NSAIDs cause quicker analgesic effects at lower 
doses and minimizing the risk of adverse events. Of the limited literature 
comparing IV APAP, PO APAP, and opioids, many studies conflict with one 
another on which options are cheaper, safer, and more effective. The differences 
in results could be related to the types of procedures used, i.e., inpatient vs. 
outpatient, gynecology vs. orthopedic, with some having better success than 
others. As there is still much uncertainty, more research into the specialized use 
of IV APAP is required to better educate physicians on when utilization may be 
warranted. 
As we continue research into multimodal pain responses and further 
understanding the contributors of pain unrelated to the procedure itself, we may 
see patterns emerge that particular risk factors such as obesity, mental health 
issues, or other traits are better treated by one medication compared to others. 
Implementing specialized, multimodal pain management regimens for these 
patients can significantly benefit not only patients and their recovery but also 




patient population of those undergoing IVF, more research is required to evaluate 
the efficiency and cost-effectiveness of IV compared to PO and opioids. This 
research could greatly benefit patients with specific characteristics that put them 
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